Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
vqbDZ7hc1Tv5tNZg